Novavax, Inc.
NASDAQ:NVAX
| Market Cap (Intraday) | 4.02B |
| Current PE | N/A |
| Forward PE | 2.2 |
| 2yr Forward PE | 5.2 |
| 10-Day MA | $45.58 |
| 50-Day MA | $49.72 |
| 200-Day MA | $116.21 |
Novavax, Inc. Stock, NASDAQ:NVAX
21 Firstfield Road, Gaithersburg, Maryland 20878
United States of America
Phone: +1.240.268.2000
Number of Employees: 1541
Description
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.